A sequencing analysis desk for hospital and college research groups
TL;DR Omicbench is a retained analysis desk for Indian research groups that outsource their sequencing and then can't make sense of the files. For a monthly fee it runs the pipelines, produces publication-ready figures and sits in on lab meetings. It is research use only, never a patient report.
India now generates genomic data at national scale. The GenomeIndia project collected 20,000 samples from 83 populations, completed whole genome sequencing for 10,000, and archived the data at the Indian Biological Data Centre with access through the FeED protocol[1]. The cohort was described in a genetics journal in April 2025[2].
The people to analyse it are the constraint. A 2026 review of India's bio-economy names a shortage of staff trained across biology, engineering and computing[3].
So what happens in practice? A clinician or a college faculty member pays a vendor for sequencing, gets a folder of FASTQ files back, and stalls. Grant money expires and students graduate with unanalysed data sitting on a hard disk.
What it does, in regulatory terms: research use only, with no patient-level report and no diagnosis. Nothing Omicbench produces goes into a medical record or guides treatment, which keeps it outside India's medical device and diagnostic rules. Any finding that could affect care goes back to the treating clinician through their own accredited lab.
A group signs a retainer of 20, 40 or 80 analyst hours a month. Omicbench takes whatever the sequencing vendor delivered, runs standard pipelines for bulk and single-cell RNA, exome and variant work, and returns figures, methods text and a short written interpretation. Analysts join the group's lab meeting every fortnight, so the back-and-forth that usually dies over email keeps moving. Reused, version-pinned pipelines are what keep the fee affordable.
The seed promised AI-powered clinical insights from multi-omics data. I moved the boundary on purpose, because clinical decision output would make this a regulated product and a much slower business. What buyers say they need is finished analysis they can publish.
The payer is the principal investigator or department head holding a grant, at medical colleges, research institutes and private hospital research arms. The budget line already exists - sequencing was paid for, so analysis is the smaller half. My test price is ₹60,000–2,00,000 a month per group, an assumption, since I found no Indian list prices for retained bioinformatics support. Core facilities at large institutes are a second buyer, paying to clear their own queue.
GenomeIndia data went into the IBDC with a formal access route in 2025[1], so more groups will work with Indian reference data than ever before. The BioE3 policy of 2024 adds bio-AI hubs to the national plan[3]. Sequencing is widely available in India from several providers, including the research services of established genomics labs[4], so the pile of groups holding unanalysed files keeps growing.
No public figure exists for Indian spending on outsourced bioinformatics analysis, and I won't make one up. The usable signal is bottom-up. GenomeIndia alone involved 20 institutions[1], and each medical college with a research cell is a candidate account. At my assumed pricing, 40 retained groups would be ₹3–8 Cr a year, which is a real services business but not a venture-scale one.
One established Indian genomics lab sells sequencing with custom bioinformatics, single-cell and spatial analysis, mostly bundled with its own lab work[4]. A data platform from an Indian AI firm serves pharma target validation and names large pharma partners[5]. Both aim higher than a ₹1 lakh a month academic retainer.
Freelancers fill the gap today, with no version control, no reproducibility and no cover when they vanish mid-project. The wedge is a dependable desk that works on data someone else generated.
| Difficulty | Moderate (42/100) |
| Starting capital | ₹1.2–2.4 Cr |
| Time to launch | 8–12 months |
The pipelines are published and the compute is rentable. The business risk is utilisation, because a services firm dies when analysts sit idle or when one account eats triple its hours. Scope creep is the specific danger, since academic groups will always ask for one more figure. Hiring analysts who can write as well as compute is the other hard bit.
No product licence, as long as you stay research use only. The moment you issue a patient report you move into diagnostic territory.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't trust AI to interpret results for any clinical purpose. This is research use only, and a model's summary of a gene list is a starting point for the analyst, not a finding.
Want to work out the AI layer for Omicbench? Talk to Yash →
I think this is a sensible first business for a bioinformatician who has published and can manage a small team. If you're chasing a product multiple then look elsewhere, because this is a services company unless the pipelines later go self-serve. Prove one thing before you scale - three retainers running for six months with utilisation above 70% and no renegotiated scope.
Plan for roughly ₹1.2–2.4 Cr, most of it on salaries for analysts and compute before retainers cover the team.
Not if you stay research use only, with no patient reports. You still need the client's ethics approval for human samples, DPDP compliance and IBDC approval for national datasets.
Yes, research groups everywhere struggle with their sequencing files. Follow your local data protection and research ethics rules, and expect more competition in big research hubs.
The free Omicbench validation kit has the line-by-line capital breakdown, the effort scoring, the ethics and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for principal investigators, and 5 assumptions to test. Download the kit →
Thinking about building Omicbench or something close to it? The make-or-break bit is holding scope on a retainer while keeping analysts busy enough to pay for themselves, and I've got opinions on how to price that. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.